Immune Design Corp (NASDAQ:IMDZ)’s share price traded down 8.8% on Wednesday . The stock traded as low as $3.05 and last traded at $3.10. 1,401,127 shares traded hands during trading, an increase of 293% from the average session volume of 356,714 shares. The stock had previously closed at $3.40.

A number of equities analysts have recently commented on the company. ValuEngine upgraded Immune Design from a “strong sell” rating to a “sell” rating in a report on Thursday, May 17th. Zacks Investment Research upgraded Immune Design from a “hold” rating to a “buy” rating and set a $5.00 target price for the company in a report on Tuesday, June 19th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have issued a buy rating to the company. Immune Design has an average rating of “Hold” and a consensus target price of $10.75.

The firm has a market capitalization of $168.58 million, a P/E ratio of -1.84 and a beta of 1.79.

Immune Design (NASDAQ:IMDZ) last announced its earnings results on Wednesday, August 1st. The biotechnology company reported ($0.29) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.30) by $0.01. The firm had revenue of $0.76 million during the quarter, compared to analysts’ expectations of $0.64 million. Immune Design had a negative return on equity of 46.95% and a negative net margin of 2,324.21%. equities analysts anticipate that Immune Design Corp will post -1.27 earnings per share for the current year.

Several institutional investors have recently made changes to their positions in IMDZ. BVF Inc. IL boosted its holdings in shares of Immune Design by 179.4% in the 1st quarter. BVF Inc. IL now owns 4,106,200 shares of the biotechnology company’s stock worth $13,550,000 after purchasing an additional 2,636,400 shares during the period. BlackRock Inc. boosted its holdings in shares of Immune Design by 80.1% in the 4th quarter. BlackRock Inc. now owns 1,868,078 shares of the biotechnology company’s stock worth $7,285,000 after purchasing an additional 830,861 shares during the period. Portolan Capital Management LLC purchased a new position in shares of Immune Design in the 2nd quarter worth approximately $2,024,000. Dimensional Fund Advisors LP boosted its holdings in shares of Immune Design by 132.4% in the 2nd quarter. Dimensional Fund Advisors LP now owns 447,026 shares of the biotechnology company’s stock worth $2,034,000 after purchasing an additional 254,696 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of Immune Design by 130.5% in the 4th quarter. Geode Capital Management LLC now owns 284,690 shares of the biotechnology company’s stock worth $1,110,000 after purchasing an additional 161,168 shares during the period. Hedge funds and other institutional investors own 50.83% of the company’s stock.

Immune Design Company Profile (NASDAQ:IMDZ)

Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. The company primarily develops oncology product candidates based on its ZVex and GLAAS discovery platforms. Its lead products include CMB305, a cancer vaccine targeting the NY-ESO-1 tumor antigen, which is in Phase 2 trial for the treatment of patients with synovial and MRCL sarcoma as a monotherapy; and G100, an antigen agnostic intratumoral product candidate as a monotherapy and combination therapy for the treatment of patients with follicular non-Hodgkin Lymphoma.

Further Reading: Closed-End Mutual Funds (CEFs)

Receive News & Ratings for Immune Design Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immune Design and related companies with MarketBeat.com's FREE daily email newsletter.